You have free access to this content

Cancer

Cover image for Cancer

1 March 2003

Volume 97, Issue 5

Pages 1139–1367

  1. Original Articles

    1. Top of page
    2. Original Articles
    3. Correspondence
    4. Book Review
    5. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Refined measurement of outcome for adjuvant breast carcinoma therapy (pages 1139–1146)

      John W. Gamel, Gianni Bonadonna, Pinuccia Valagussa and Michael J. Edwards

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11171

      • original image
      • original image

      To measure the long-term benefit of adjuvant breast carcinoma therapy, we must consider both the impact of treatment and the age-dependent life expectancy of each patient. When appropriately combined, this information provides an explicit comparison, in terms of years of added survival, between two or more arms of a controlled clinical trial.

    2. You have free access to this content
      5-Year mammography rates and associated factors for older women (pages 1147–1155)

      R. Van Harrison, Nancy K. Janz, Robert A. Wolfe, Philip J. Tedeschi, Xuelin Huang and Laurence F. McMahon Jr.

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11172

      Even with screening mammography as a covered benefit for the 5 years between 1993–1997, 43% of a representative sample of 10,000 female Medicare beneficiaries (age ≥ 65 years in 1993) in Michigan had no evidence of having undergone a mammogram and 16% had evidence of only 1 mammogram. Intervention efforts should emphasize screening based on functional status rather than age, and this message should be targeted to physicians and to older women without claims for recent mammograms.

    3. You have free access to this content
      Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? (pages 1156–1163)

      Gabriele Martelli, Rosalba Miceli, Giuseppe De Palo, Danila Coradini, Bruno Salvadori, Roberto Zucali, Emanuele Galante and Ettore Marubini

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11173

      • original image

      This retrospective analysis, which included 671 consecutive patients with breast carcinoma who were age ≥ 70 years and without palpable axillary lymph nodes who were treated with quadrantectomy and tamoxifen, demonstrated no difference in breast carcinoma mortality between patients who underwent axillary lymph node dissection and patients who did not. Lymphadenectomy, therefore, should be delayed and reserved for the small proportion of elderly women who later develop overt lymphadenopathy.

    4. You have free access to this content
      Evaluation of an internet support group for women with primary breast cancer (pages 1164–1173)

      Andrew J. Winzelberg, Catherine Classen, Georg W. Alpers, Heidi Roberts, Cheryl Koopman, Robert E. Adams, Heidemarie Ernst, Parvati Dev and C. Barr Taylor

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11174

      Women with primary breast carcinoma were assigned randomly to a web-based, moderated, asynchronous social support or control group. Compared with the control group women, women in the intervention group significantly reduced their depression, cancer-related trauma, and stress levels.

    5. You have free access to this content
      Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma (pages 1174–1180)

      Marco Venturini, Antonio Durando, Ornella Garrone, Maria Antonietta Colozza, Antonio Contu, Ilaria Stevani, Franco Genta, Claudia Bighin, Antonio Lambiase and Lucia Del Mastro

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11203

      • original image

      This Phase II study demonstrates that oral capecitabine in combination with docetaxel and epirubicin (TEX) has an important antitumor activity and an acceptable safety profile as first-line treatment for patients with locally advanced/metastatic breast carcinoma. A large, randomized, Phase III trial is ongoing to compare the TEX regimen with a regimen of epirubicin plus docetaxel in patients with untreated, advanced breast carcinoma.

    6. Endocrine Diseases
      You have free access to this content
      Pure versus follicular variant of papillary thyroid carcinoma : Clinical features, prognostic factors, treatment, and survival (pages 1181–1185)

      Jamal Zidan, Drumea Karen, Moshe Stein, Edward Rosenblatt, Walid Basher and Abraham Kuten

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11175

      • original image
      • original image
      • original image

      The authors performed a clinicopathologic comparison of 143 patients with pure papillary thyroid carcinoma and 100 patients with the follicular variant of papillary thyroid carcinoma. Prognostic features, age, tumor size, stage, capsular invasion, treatment, and 21-year overall survival were similar for both groups.

    7. You have free access to this content
      Prognostic factors in patients with Hürthle cell neoplasms of the thyroid (pages 1186–1194)

      Luis Lopez-Penabad, Alice C. Chiu, Ana O. Hoff, Pamela Schultz, Sonia Gaztambide, Nelson G. Ordoñez and Steven I. Sherman

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11176

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Hürthle cell carcinomas are an aggressive type of thyroid carcinoma with a propensity for locoregional and distant metastasis. The authors identified several clinical and pathologic factors that predict disease progression and death in patients with Hürthle cell neoplasms.

    8. Gastrointestinal Tract
      You have free access to this content
      Cisplatin-based combined modality therapy for anal carcinoma : A wider therapeutic index (pages 1195–1202)

      Arthur Hung, Christopher Crane, Marc Delclos, Matthew Ballo, Jaffer Ajani, Edward Lin, Barry Feig, John Skibber and Nora Janjan

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11161

      Combined modality therapy with continuous infusion of cisplatin and 5-fluorouracil (5-FU) is a well tolerated regimen that results in high rates of local control, survival, and sphincter preservation. These rates are comparable to the best results reported with mitomycin-C and 5-FU. Without the normally severe toxicity, cisplatin-based therapy results in a wider therapeutic index.

    9. Genitourinary Tract
      You have free access to this content
      Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy (pages 1203–1210)

      Nicole L. Miller, Eric A. Bissonette, Robert Bahnson, John Wilson and Dan Theodorescu

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11177

      • original image
      • original image
      • original image

      Hormone deprivation using a luteinizing hormone-releasing hormone agonist decreases the quality of life of patients undergoing radiotherapy for prostate carcinoma. A cross-sectional study was undertaken to evaluate the impact of a novel approach to neoadjuvant and adjuvant hormone-deprivation therapy using antiandrogen and finasteride on quality of life (QOL), voiding function, and sexual function in patients with localized prostate carcinoma who were treated with brachytherapy. The results demonstrate that this approach is associated with an overall QOL equal to that of brachytherapy alone for the treatment of patients with localized prostate carcinoma.

    10. You have free access to this content
      Elevation of cytokine levels in cachectic patients with prostate carcinoma (pages 1211–1216)

      Jesco Pfitzenmaier, Robert Vessella, Celestia S. Higano, Jennifer L. Noteboom, David Wallace Jr. and Eva Corey

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11178

      • original image

      Approximately 60–70% of patients with advanced prostate carcinoma (CaP) suffer from cachexia, one of the most devastating conditions associated with advanced malignant disease. It has been proposed that several cytokines are involved in the development of cachexia. The authors found that levels of tumor necrosis factor α, interleukin 6, and interleukin 8 are increased in patients with advanced cachectic CaP compared with patients with advanced noncachectic CaP and that these cytokines play a role in CaP cachexia.

    11. You have free access to this content
      High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma (pages 1217–1224)

      Tomasz M. Beer, Dianne Lemmon, Bruce A. Lowe and W. David Henner

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11179

      • original image
      • original image

      Weekly administration of high-dose calcitriol has been found to be safe, even over prolonged periods of time. Of 22 patients, three (14%) had prostate specific antigen (PSA) reductions that ranged from 10–47%. An additional three patients (14%) had statistically significant increases in PSA doubling time with this regimen.

    12. You have free access to this content
      Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients (pages 1225–1233)

      Takefumi Satoh, Guang Yang, Shin Egawa, Josephine Addai, Anna Frolov, Sadahito Kuwao, Terry L. Timme, Shiro Baba and Timothy C. Thompson

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11198

      • original image
      • original image
      • original image

      Caveolin-1 overexpression has been shown to have prognostic value in American men with clinically determined, localized prostate carcinoma, independent of pathologic parameters. The current study demonstrates that caveolin-1 expression also is predictive of a shorter time to disease recurrence after radical prostatectomy in Japanese men with pathologically determined, localized prostate carcinoma.

    13. Hematologic Malignancies
      You have free access to this content
      A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome (pages 1234–1241)

      Jorge Cortes, Hagop Kantarjian, Maher Albitar, Deborah Thomas, Stefan Faderl, Charles Koller, Guillermo Garcia-Manero, Francis Giles, Michael Andreeff, Susan O'Brien, Michael Keating and Elihu Estey

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11180

      • original image
      • original image
      • original image

      Because angiogenesis may play a role in acute myeloid leukemia or high-risk myelodysplastic syndrome, thalidomide was combined with chemotherapy to treat patients with these diseases. Although pretreatment vascular endothelial growth factor levels predicted for survival, thalidomide was found to have no effect on response or long-term outcome.

    14. You have free access to this content
      Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias (pages 1242–1247)

      Marcos de Lima, Farhad Ravandi, Munir Shahjahan, Borje Andersson, Daniel Couriel, Michele Donato, Issa Khouri, James Gajewski, Koen van Besien, Richard Champlin, Sergio Giralt and Hagop Kantarjian

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11184

      • original image

      Decitabine was combined with busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients with high-risk leukemias. At a median of 3.3 years posttransplantation, 26% of patients were alive and disease free.

    15. You have free access to this content
      Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia (pages 1248–1252)

      Srdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, Jorge Cortes, Stefan Faderl, Francis J. Giles, Michael Keating and Maher Albitar

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11217

      • original image
      • original image
      • original image
      • original image

      Telomerase activity appears to be elevated in bone marrow samples from patients with many malignant hematologic diseases. Data from the current study demonstrate that patients having chronic phase chronic myeloid leukemia with high telomerase activity progress sooner to advanced phase disease and have significantly shorter survival than patients with low telomerase activity.

    16. Hepatobiliary Tract
      You have free access to this content
      Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation (pages 1253–1262)

      Yasuji Komorizono, Makoto Oketani, Katsumi Sako, Naruhiro Yamasaki, Toshihiko Shibatou, Masahiko Maeda, Kazunori Kohara, Shuhou Shigenobu, Kazuaki Ishibashi and Terukatsu Arima

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11168

      • original image
      • original image
      • original image

      For the treatment of patients with small hepatocellular carcinomas who have tumors that measure ≤ 3 cm in greatest dimension, a single session, single application of radiofrequency ablation can result in favorable local control, depending on multiple factors. In this study, tumor size and tumor location were associated significantly with the local recurrence free interval.

    17. Lung Disease
      You have free access to this content
      Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers (pages 1263–1270)

      Maria P. Wong, Lai-Fan Fung, Elaine Wang, Wing-Shun Chow, Shui-Wah Chiu, Wah-Kit Lam, Kwok-Keung Ho, Edmond S. K. Ma, Thomas S. K. Wan and Lap-Ping Chung

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11183

      • original image
      • original image

      Primary lung adenocarcinomas in nonsmokers show distinct DNA gains at 16p. Other chromosomal aberrations involve common oncogenic and tumor suppressor loci and suggest overlapping pathogenetic targets with lung carcinomas that arise in smokers.

    18. You have free access to this content
      Overdiagnosis in chest radiographic screening for lung carcinoma : Frequency (pages 1271–1275)

      David F. Yankelevitz, William J. Kostis, Claudia I. Henschke, Robert T. Heelan, Daniel M. Libby, Mark W. Pasmantier and James P. Smith

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11185

      Results obtained from the Mayo Lung Project (MLP), which provided the basis for the prevailing recommendations against radiographic screening for lung carcinoma, have led to the assertion that as many as 50% of diagnosed cases of early-stage lung carcinoma in that trial may have represented overdiagnosed, indolent cases, suggesting the possibility of such a high frequency of overdiagnosis in chest radiographic lung carcinoma screening in general. In the current study, the authors analyzed data from the MLP and its Memorial Sloan-Kettering Cancer Center counterpart to estimate the frequency of overdiagnosis in chest radiographic screening for lung carcinoma.

    19. Neuro-Oncology
      You have free access to this content
      Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features (pages 1276–1284)

      Martin J. van den Bent, Leendert H. J. Looijenga, K. Langenberg, Winand Dinjens, Wilfried Graveland, Ludo Uytdewilligen, Peter A. Sillevis Smitt, Robert B. Jenkins and Johan M. Kros

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11187

      • original image
      • original image
      • original image

      Patients with oligodendroglioma lesions that demonstrate a combined loss of chromosomes 1p and 19q respond better to chemotherapy and radiotherapy. These tumors have less aggressive clinical behavior before initial treatment compared with lesions that do not have combined loss of 1p and 19q. This type of oligodendroglioma constitutes a different biologic entity and requires separate clinical trials.

    20. Sarcoma
      You have free access to this content
      Extraskeletal myxoid chondrosarcoma : A multi-institutional study of 42 cases in Japan (pages 1285–1292)

      Satoshi Kawaguchi, Takuro Wada, Satoshi Nagoya, Tatsuru Ikeda, Kazuo Isu, Katsushige Yamashiro, Akira Kawai, Takeshi Ishii, Nobuhito Araki, Akira Myoui, Seiichi Matsumoto, Tohru Umeda, Hideki Yoshikawa and Tadashi Hasegawa

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11162

      • original image
      • original image
      • original image
      • original image

      Forty-two cases of extraskeletal myxoid sarcoma were analyzed for histologic grade, demographics, treatments, outcomes, and prognostic factors in a multi-institutional retrospective study. The results supported the role of wide excision in the local control of extraskeletal myxoid sarcoma and its biologic nature as an intermediate malignancy.

    21. Discipline

      Epidemiology
      You have free access to this content
      Mammography screening among Chinese-American women (pages 1293–1302)

      Shin-Ping Tu, Yutaka Yasui, Alan A. Kuniyuki, Stephen M. Schwartz, J. Carey Jackson, Thomas Gregory Hislop and Vicky Taylor

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11169

      The authors recommend a multifaceted approach to promote mammography screening among Chinese-American women: physician recommendations and education regarding the effectiveness of mammography compared with breast self-examination and clinical breast examination.

    22. You have free access to this content
      Socioeconomic status and breast carcinoma survival in four racial/ethnic groups : A population-based study (pages 1303–1311)

      Cynthia D. O'Malley, Gem M. Le, Sally L. Glaser, Sarah J. Shema and Dee W. West

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11160

      • original image
      • original image

      After adjusting for clinical, demographic, and socioeconomic factors, blacks were 22% more likely to die of breast carcinoma than whites, whereas the survival rates among Asians/Pacific Islanders and Hispanics survival did not differ from whites. Residing in a blue-collar neighborhood was associated with a 16% increase in the risk of death from breast carcinoma, independent of race/ethnicity.

    23. Medical Oncology
      You have free access to this content
      A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease (pages 1312–1320)

      John A. Glaspy, Jaswant Sinh Jadeja, Glen Justice, Alex Fleishman, Gregory Rossi and Alan B. Colowick

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11186

      • original image
      • original image
      • original image
      • original image

      Darbepoetin α, given in a front-loaded dose for 4 weeks followed by lower and/or less frequent doses, appears to be efficacious and may decrease the time to response compared with recombinant human erythropoietin.

    24. Pathology
      You have free access to this content
      Ki-67 expression in breast carcinoma : Its association with grading systems, clinical parameters, and other prognostic factors—A surrogate marker? (pages 1321–1331)

      Helen Trihia, Susan Murray, Karen Price, Richard D. Gelber, Rastko Golouh, Aron Goldhirsch, Alan S. Coates, John Collins, Monica Castiglione-Gertsch and Barry A. Gusterson

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11188

      • original image
      • original image

      Standardized pathologic grade is considered one of the few prognostic and predictive factors that has proven value for patients with breast carcinoma. The authors assessed Ki-67 as a measure of tumor proliferation that can be used in fine-needle aspirates and small biopsies and concluded that Ki-67 is a good objective substitute for mitotic counts when it is used in a grading system.

    25. Pediatric Oncology
      You have free access to this content
      Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine (pages 1332–1338)

      Alberto Garaventa, Claudio Gambini, Giampiero Villavecchia, Andrea Di Cataldo, Luigi Bertolazzi, Maria Rosa Pizzitola, Bruno De Bernardi and Riccardo Haupt

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11167

      • original image

      Of 119 neuroblastoma patients treated with 131I-metaiodobenzylguanidine (131I-MIBG), 5 cases of second malignancies occurring between 1 and 14 years after radiometabolic therapy were observed. There was one case each of acute myeloid leukemia, chronic myelomonocytic leukemia, angiomatous malignant fibrous histiocytoma, malignant schwannoma, and rhabdomyosarcoma. If 131I-MIBG treatment becomes more broadly employed in the therapeutic strategy for neuroblastoma patients, the risk of secondary cancer should be taken into consideration.

    26. You have free access to this content
      Childhood cancer patients' access to cooperative group cancer programs : A population-based study (pages 1339–1345)

      Lihua Liu, Mark Krailo, Gregory H. Reaman and Leslie Bernstein

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11192

      • original image

      This record linkage study attempted to determine the proportion of children diagnosed with cancer who are registered with pediatric cooperative clinical trials groups. Registration rates were found to vary by age at diagnosis, cancer type, stage of disease, and geography, and appear to provide coverage of only 57% of cancers diagnosed among children age < 20 years.

    27. Radiation Oncology
      You have free access to this content
      Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma (pages 1346–1352)

      Junji Furuse, Taira Kinoshita, Mitsuhiko Kawashima, Hiroshi Ishii, Michitaka Nagase, Masaru Konishi, Toshio Nakagohri, Kazuto Inoue, Takashi Ogino, Hiroshi Ikeda, Yasushi Maru and Masahiro Yoshino

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11165

      • original image
      • original image
      • original image

      The authors conducted a Phase II study of chemoradiotherapy with intensive radiotherapy, using a combination of intraoperative radiotherapy, conformal external-beam radiotherapy, and protracted 5-fluorouracil for patients with locally advanced pancreatic carcinoma. This regimen of chemoradiotherapy is not superior to conventional chemoradiotherapy.

    28. You have free access to this content
      Oral pseudotumor : Benign polypoid masses following radiation therapy (pages 1353–1357)

      Sayako Oota, Hitoshi Shibuya, Miwako Hamagaki, Ryo-ichi Yoshimura, Hiroshi Iwaki, Masaru Kojima and Minoru Takagi

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11164

      • original image
      • original image
      • original image
      • original image

      Oral carcinoma patients treated with radiation therapy may develop benign polypoid masses diagnosed as pseudotumors. The current study describes clinical and pathologic features of pseudotumors. The incidence rate of pseudotumors was 0.22%, and they were curable with surgery.

    29. Translational Research
      You have free access to this content
      Nitric oxide suppression triggers apoptosis through the FKHRL1 (FOXO3A)/ROCK kinase pathway in human breast carcinoma cells (pages 1358–1363)

      Zivotije Radisavljevic

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.10081

      • original image
      • original image
      • original image
      • original image

      This novel unknown phenomenon of breast carcinoma cell apoptosis was triggered by NO suppression, which promotes FKHRL1 thr-32-enhanced phosphorylation and initiates signaling of FKHRL1 to ROCK kinase as an effector molecule. This apoptotic signalling process is caspase-3 as well as PI3K/Akt independent.

  2. Correspondence

    1. Top of page
    2. Original Articles
    3. Correspondence
    4. Book Review
    5. Errata
    1. You have free access to this content
      Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma (page 1364)

      Leslie H. Sobin and Frederick L. Greene

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11182

    2. You have free access to this content
      Author reply (page 1365)

      Aleodor A. Andea, Tracie Wallis, Lisa A. Newman, David Bouman, Jyotirmoy Dey and Daniel W. Visscher

      Version of Record online: 20 FEB 2003 | DOI: 10.1002/cncr.11163

  3. Book Review

    1. Top of page
    2. Original Articles
    3. Correspondence
    4. Book Review
    5. Errata
    1. You have free access to this content
  4. Errata

    1. Top of page
    2. Original Articles
    3. Correspondence
    4. Book Review
    5. Errata
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION